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ABSTRACT 
BACKGROUND 
Two popular operational definitions of frailty, the frailty phenotype and Frailty Index (FI), are 
based on different theories. Although FI was shown to be superior in predicting mortality to 
the frailty phenotype, no meta-analysis on mortality risk according to FI has been found in 
the literature. 
 
METHODS 
An electronic systematic literature search was conducted in August 2016 using four databases 
(Embase, Medline, CINAHL and PsycINFO) for prospective cohort studies published in 2000 
or later, examining the mortality risk according to frailty measured by FI.  A meta-analysis 
was performed to synthesise pooled mortality risk estimates. 
 
RESULTS 
Of 2,617 studies identified by the systematic review, 18 cohorts from 19 studies were 
included. Thirteen cohorts showed hazard ratios (HRs) per 0.01 increase in FI, six cohorts 
showed HRs per 0.1 increase in FI and two cohorts each showed odds ratios (ORs) per 0.01 
and 0.1 increase in FI, respectively. All meta-analyses suggested that higher FI was 
significantly associated with higher mortality risk (pooled HR per 0.01 FI increase=1.039, 
95%CI=1.033-1.044, p<0.001; pooled HR per 0.1 FI increase=1.282, 95%CI=1.258-1.307, 
p<0.001; pooled OR per 0.01 FI increase=1.054, 95%CI=1.040-1.068, p<0.001; pooled OR 
per 0.1 FI increase=1.706, 95%CI=1.547-1.881, p<0.001). Meta-regression analysis among 
13 cohorts with HR per 0.01 increase in FI showed that the studies with shorter follow-up 
periods and with lower female proportion were associated with higher mortality risks by FI. 
 
CONCLUSIONS 
This systematic review and meta-analysis was the first to quantitatively demonstrate that 
frailty measured by the FI is a significant predictor of mortality.  
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INTRODUCTION 
Frailty has been gaining increasing scientific attention over the last few decades. Frailty is 
generally considered to be a state characterised by reduced physiological reserve and loss of  
resistance to stressors caused by accumulated age-related deficits.[1] It has been shown that 
those who are frail are predisposed to various negative health outcomes, such as falls, 
fractures, hospitalisation, nursing home placement, disability, poor quality of life and 
dementia.[2-8] 
 
Two of the most popular operational definitions of frailty are the frailty phenotype by Fried 
and colleagues, using data from the Cardiovascular Health Study,[9] and the Frailty Index 
(FI) by Rockwood, Mitnitski and colleagues, using the Canadian Study of Health and Aging 
(CSHA).[10] These two approaches are based on different theories.[11] frailty phenotype 
describes frailty as a biological syndrome with specific phenotypic presentations and defines 
frailty as having three or more of five physical components: unintentional weight loss; self-
reported exhaustion; weakness; slow walking speed; and low physical activity.[9] The frailty 
phenotype is a well-validated and the most frequently used measure in research and clinical 
practice. On the other hand, this definition has been criticised for being quite narrow in focus, 
and for not including potentially important components of frailty such as cognitive 
impairment.[1, 12, 13] By contrast, the concept of the FI is that frailty is a state caused by the 
accumulation of health deficits during the life course and that the more deficits one has, the 
more likely one is to be frail.[10] The FI is calculated as a ratio of the number of deficits 
present to the number of total deficits considered.[10] The deficits can be symptoms, signs, 
diseases, disabilities, laboratory, radiographic, or electrocardiographic abnormalities and 
social characteristics.[14] While the exact operationalisation of the FI has varied between 
studies, standard criteria for constructing a FI are used.[14]  
Frailty is a strong predictor of mortality,[1] as has been shown by previous systematic 
reviews.[15-17] Two of these reviews systematically collected studies that used different 
frailty definitions, including frailty phenotype and the FI, and demonstrated that frailty 
consistently increased the risk of death in most studies.[15, 16] These reviews just listed 
mortality risk estimates per different units of the FI from the original papers, therefore it is 
not possible to directly compare these estimates and no meta-analysis was conducted.[15, 16] 
The third paper conducted a meta-analysis using the data from only studies using frailty 
phenotype and showed frailty and pre-frailty significantly predicted mortality in a graded 
manner.[17] Although the FI was shown to be superior in predicting mortality and other 
health outcome risks to frailty phenotype in a head-to-head comparison,[18, 19] to the best of 
our knowledge, no meta-analysis on mortality risk according to the FI has been found in the 
literature. This may be partially because the previous studies provided mortality risks 
according to different units of the FI, such as per 0.01 of the FI, 0.1 of the FI or per additional 
deficit, or according to frailty groups based on arbitrary cutpoints of the FI. Therefore, the 
objectives of this study are as follows: (1) to conduct a systematic search of the literature for 
prospective studies examining mortality risk according to frailty defined by the FI; and (2) to 
combine the effect sizes to synthesise pooled risk estimates of mortality by standard units of 
the FI, per 0.01 or 0.1 of the FI’s increment. 
 
METHOD  
Data source and search strategy 
An electronic systematic literature search was conducted in August 2016 by a clinician 
researcher (GK) based on a protocol developed according to the PRISMA statements.[20] 
Embase, Medline, CINAHL Plus and PsycINFO were searched for studies published in 2000, 
given that the first FI paper was published in 2001,[10] or later using a combination of 
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Medical Subject Heading (MeSH) and text terms without language restriction. The search 
terms used were (“Mortality (MeSH)” OR “Death (MeSH)” OR “Death and Dying” OR 
“mortality” OR “death*”) AND (“Rockwood K (as author)” OR “Mitnitski A (as author)” OR 
“Rockwood” OR “Mitnitski” OR “frailty index” OR “FI”). The names of Professors 
Rockwood and Mitnitski were used as a search term as they developed the FI and have since 
published multiple papers using the FI. We also repeated the literature search in July 2017 
using “accumulated deficit*”, “cumulative deficit*” and “deficit accumulation” along with 
abovementioned mortality related terms for additional studies. References of the relevant 
articles and reviews were also reviewed for additional studies. Forward citation tracking was 
also conducted on Google Scholar website for the three previous review papers.[15-17] 
 
Eligibility criteria 
The following inclusion and exclusion criteria were used. 
Inclusion criteria: 
1. Prospective study design 
2. Adult population with mean age of 20 or greater 
3. More than half of the cohort in the community (CSHA included approximately 10% of 
institutionalised people[10]) 
3. Baseline frailty defined by the FI constructed according to the published standard 
methodology[14] 
4. Subsequent all-cause mortality risk assessed as hazard ratio (HR) or odds ratio (OR) per 
0.01 or 0.1 increase in FI 
Exclusion criteria: 
1. Selected populations, such as ones with a certain disease or medical condition 
2. Mortality risk per additional deficit or per worsening of frailty subgroups, such as by tertile 
or arbitrary cut-points. 
3. Conference presentations, review articles, editorials, comments, or dissertations. 
 
Study selection 
The studies identified by the systematic review were assessed using the above inclusion and 
exclusion criteria by one author (GK). Initially the titles and abstracts were reviewed, and full 
texts were retrieved for articles that were considered to be eligible or to need a further 
assessment for eligibility. The full texts and reference lists were examined to identify 
potentially eligible studies. The original authors were contacted for clarification, if needed. If 
multiple studies showed the same effect measures using the same cohort, or one study 
provided multiple results with different conditions, such as for different follow-up periods, 
the results with the larger number of cohorts, the larger number of deficits used to construct 
the FI, or longer durations were selected. Each cohort only contributed data once per meta-
analysis. 
 
Data extraction 
Data extracted from the included studies by the author (GK), using a standardised form, were 
first author, study name if any, publication year, location, population characteristic, sample 
size, proportion of female participants, mean age, age range, number of deficits used to create 
the FI and follow-up period. HRs or ORs of all-cause mortality per 0.01 or 0.1 increase in the 
FI along with 95% confidence interval (CI) were also collected. The effect measures adjusted 
confounders were preferred over crude ones. 
 
See Appendix 1 for methodological quality assessment and statistical analysis. 
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RESULTS 
Selection processes 
The systematic search of the literature using four electronic databases (Embase, MEDLINE, 
CINAHL Plus and PsycINFO) yielded 2,611 studies. Six additional studies were found by 
other source. Of the 2,617 studies, 651 duplicate studies were excluded. The title and abstract 
screening further excluded 1,891 studies, leaving 75 studies. Full-text review of these 75 
studies excluded 56, due to the following reasons: no HR or OR for mortality provided 
(n=25); effect measures per change in frailty groups based on the FI (n=17); effect measures 
per each additional deficit (n=4); non-standard FI used (n=3); the same cohort used (n=3); 
selected population (hospitalized patients) (n=1);unit of the FI for effect measures not clearly 
documented (n=3). Among these excluded studies, the findings of 28 studies providing 
mortality risks as HR or OR by frailty status based on the FI in general adult populations 
were summarised in Appendix 2. All the studies consistently showed worse frailty status 
defined by the FI in various ways, such as per deficit or grouping, was significantly 
associated with higher mortality risks. 
 
Nineteen studies were left (the references are listed in Appendix 3) and assessed for 
methodological quality using the modified 8-item Newcastle-Ottawa scale. All studies met 
five or more of the eight items and were considered to have adequate methodological quality 
(range=5-7, mean=6.1).  
Two studies provided HR per 0.01 increase in the FI using the Survey of Health, Ageing and 
Retirement in Europe (SHARE).[23, 24] The study with the larger number (n=37,546) 
showed that all of adjusted hazard ratio and upper and lower limits of 95% CI were the same 
at 1.04 (aHR=1.04, 95%CI=1.04-1.04),[23] which was not possible to be included in the 
meta-analysis. Therefore, the other study (n=36,306) was used instead (aHR=1.05, 
95%CI=1.05-1.06).[24] A study showed 2-year, 4-year and 7-year mortality risks (age- and 
gender-adjusted HRs=1.04 (95%CI=1.03-1.04), 1.03 (95%CI=1.03-1.04) and 1.03 
(95%CI=1.03-1.03), respectively).[25] Since the 7-year mortality HR could not be used for 
the same reason above, the 4-year mortality HR was used for the meta-analysis instead. One 
study was included after confirmation with the study authors regarding a FI unit used to 
calculate the effect measures (HR per 0.1 increase in the FI).[26] Additional data (HR per 
0.01 increase in the FI) were also provided by the authors of this study[26] and included in 
the meta-analysis. Four series of meta-analyses were conducted for HR per 0.01 increase in 
the FI (n=12), HR per 0.1 increase in the FI (n=4), OR per 0.01 increase in the FI (n=2) and 
OR per 0.1 increase in the FI (n=2). A flow chart of the systematic literature review is shown 
in Figure 1.  
 
Characteristics of selected studies 
Table 1 presents characteristics and outcomes of the included studies. A total of 18 cohorts 
were used by 19 studies, which were summarised according to unit of the FI used to calculate 
effect measures (HR per 0.01 of the FI, HR per 0.1 of the FI, OR per 0.01 of the FI, OR per 
0.1 of the FI). Four cohorts from Canada were used by six studies,[23, 27-31] three cohorts 
from the UK were used by two studies,[32, 33] four cohorts from the US were used by four 
studies,[14, 18, 34, 35] four cohorts from China were used by three studies,[25, 26, 36] two 
cohorts, both of which consisted of multinational European populations, were used by three 
studies[24, 37, 38] and lastly one Dutch cohort was used by one study.[39] The sample sizes 
ranged from 754[14] to 36,306[24]. Two female only cohorts were used by three studies[28, 
29, 32] and two male only cohorts were used by three studies.[35, 37, 38] The remaining 
cohorts were mixed with approximately 50-70% women. The number of deficits used to 
create the FI ranged from 23[23] to 70.[24, 31] The follow-up periods varied with the shortest 
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of 2 years[24, 33] and the longest of 19 years.[39] Twelve studies provided HR for mortality 
risk per 0.01 increase in the FI for 13 cohorts,[14, 18, 23, 25-27, 30, 31, 34, 36, 37, 39] four 
studies provided HR per 0.1 increase in the FI for six cohorts,[26, 31, 32, 38] two studies 
provided OR per 0.01 increase in the FI for two cohorts,[28, 33] and two studies provided OR 
per 0.1 increase in the FI for two cohorts.[29, 35] All included studies provided effect 
measures adjusted for at least age and gender, or age only in male only or female only 
cohorts, except for one study[18] providing an unadjusted effect measure. 
 
Frailty Index as a predictor of mortality 
Meta-analysis of studies using HR 
HRs of mortality per 0.01 increase in the FI from the 13 cohorts were combined using a 
random-effects model due to the significant heterogeneity (p<0.001, I2=86%). Frailty was a 
significant predictor of mortality (13 cohorts: pooled HR=1.039, 95%CI=1.033-1.044, 
p<0.001). Combining HRs per 0.1 increase in the FI from six cohorts using a fixed-effect 
model (heterogeneity p=0.11, I2=45%) also showed that frailty significantly predicted 
mortality (6 cohorts: pooled HR=1.282, 95%CI=1.258-1.307, p<0.001). (Figure 2 A B) 
 
Meta-analysis of studies using OR 
Four studies provided OR as a risk measure of mortality. Two studies showed ORs per 0.01 
increase in the FI[28, 33] and another two studies showed ORs per 0.1 increase in the FI.[29, 
35] fixed-effects models were used (heterogeneity p=0.23 and 0.24, I2=30% and 29%, 
respectively) and both showed that frailty is a significant predictor of mortality (2 cohorts: 
pooled OR per 0.01 increase in the FI=1.054, 95%CI=1.040-1.068, p<0.001; 2 cohorts: 
pooled OR per 0.1 increase in the FI=1.706, 95%CI=1.547-1.881, p<0.001, respectively). 
(Appendix 4 A B) 
 
See Appendix 1 for meta-regression and subgroup analysis and publication bias assessment. 
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DISCUSSION 
The current study identified 19 studies that longitudinally examined mortality risk according 
to frailty measured by the FI in 18 cohorts and provided the effect measured as HR or OR per 
0.01 or 0.1 increase in the FI. The meta-analysis quantitatively combined mortality risks 
based on frailty measured by the FI and consistently showed increased mortality risk 
according to the FI regardless of different types of the effect sizes and per units of the FI.. 
Although the included studies constructed the FI based on different numbers and types of 
deficits, in addition to various populations and study settings, it is of note that the effect 
measures were in relatively narrow ranges and may support the robustness of this 
accumulation deficit frailty model. 
 
Although in general age is a strong predictor of mortality, the mean age of the cohorts was 
not a significant modulator in the association between the FI and mortality in the meta-
regression analysis. Furthermore, subgroup analysis also showed that pooled estimates of 
studies with a mean age of >65[14, 18, 24-26, 30, 36] and <65[23, 27, 37] (mostly middle 
aged with the mean age ranging from 44 to 60.2) were almost identical (8 cohorts: pooled 
HR=1.04, 95%CI=1.03-1.05, p<0.001, I2=84%, 3 cohorts: pooled HR=1.05, 95%CI=1.03-
1.07, p<0.001, I2=92%, respectively). This suggests the FI is a good indicator of mortality 
risk not only among older people but also among younger populations, regardless of age.  
 
Two study characteristics were found in the meta-regression analysis to be related to the 
association between frailty and mortality: follow-up period and female proportion. In general, 
women live longer but have more disabilities than men, known as the male-female health-
survival paradox.[40] Given the FI can be regarded as a measure of biological age[10] and 
prevalence of frailty is higher among women than men,[9] it is to be expected that female 
gender is associated with lower mortality risk according to frailty in the meta-regression 
analysis.  Regarding the follow-up period, the meta-regression analysis suggests shorter 
follow-up periods are associated with higher mortality risk according to the FI. Frailty is a 
dynamic state and known to change over time, mostly worsening rather than improving.[41] 
The longer follow-up periods imply that as participants get older they usually get frailer. This 
may be why the reason the association between frailty and mortality became less prominent 
in studies with longer follow-up periods. The studies using the same cohorts with different 
lengths of follow-up showed overall comparable results with little difference.[14, 23, 24] In 
SHARE, 2-year mortality (aHR=1.05)[24] was slightly higher than 5-year mortality 
(aHR=1.04),[23] while 9-year mortality (aHR=1.03)[14] was slightly lower than 12-year 
mortality (aHR=1.04)[23] in the Yale Precipitating Events Project. 
 
This study’s findings should be interpreted with caution due to some limitations. First, all 
processes of the systematic review and meta-analysis were conducted by one investigator. 
Second, during the study selection, a large number of studies that used the FI to examine 
mortality risk were excluded because they did not provide HR or OR for mortality (n=25); 
the effect measures provided were based on frailty groups defined by different cut-off points 
(n=17); or on each additional deficit (n=4). Although not all, at least some of them could 
potentially have been included in the meta-analysis. Lastly, the effect measures and upper and 
lower limits of 95% CI in many of the included papers were rounded to two decimal places, 
which could potentially lead to a miscalculation of standard error or weighting in the meta-
analysis, especially when effect measures were calculated per 0.01 increase in the FI and 
were therefore relatively smaller. 
 
The current study has multiple strengths. The search strategy of the systematic review of the 
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literature was robust and reproducible, using comprehensive search terms in multiple 
electronic databases. Additional data were also acquired from the original study’s 
authors.[26] The included studies were also assessed for heterogeneity, methodological 
quality, and publication bias, and a high degree of heterogeneity was further explored by 
meta-regression analysis and subgroup analysis. The data from included studies were based 
on a FI constructed according to the standard methodology.[14] and were mostly controlled 
for important confounders, age and gender, or age in male only or female only cohorts. Other 
potential confounders would include education, socioeconomic status, smoking and alcohol 
consumption. In the subgroup analysis, there was no significant difference in mortality risk 
between studies adjusting for age and gender or age only and studies additionally adjusting 
for such confounders (8 cohorts: pooled HR=1.04, 95%CI=1.03-1.05, p<0.001, I2=89%, 4 
cohorts: pooled HR=1.04, 95%CI=1.03-1.04, p<0.001, I2=74%, respectively. P for subgroup 
difference=0.53). Lastly this is the first systematic review and meta-analysis focusing on FI 
and mortality. 
 
There are several features of the FI which distinguish it from frailty phenotype. As mentioned 
above, the FI can evaluate frailty status in a graded manner, rather than just three frailty 
categorisations by frailty phenotype (robust, pre-frail and frail), and make a more precise risk 
prediction. Furthermore, those who have a missing value for specific frailty components may 
be excluded from analyses in frailty phenotype. However the FI can still be calculated by 
excluding missing deficits from both numerator and denominator, which is because deficits 
are considered to be interchangeable if a sufficiently large number of deficits are 
included.[42] Although one may argue that it is not practical in clinical settings to collect 
information of 30 or more health deficits to calculate the FI, most of the clinical information 
could be extracted from electronic medical record systems. A recent study created an 
electronic FI from readily available data in primary care electronic records and demonstrated 
robust predictive ability for mortality, hospitalisation and nursing home placement.[43]  
 
This systematic review and meta-analysis was the first to quantitatively demonstrate the 
pooled mortality risk estimate according to frailty defined by the FI. Frailty measured by the 
FI is a strong predictor of death among older people as well as younger and middle-aged 
populations. A shorter follow-up period and lower female proportion seem to be associated 
with higher mortality risks according to frailty.  
 
ABBREVIATIONS 
CI: Confidence interval; CSHA: Canadian Study of Health and Aging; FI: Frailty Index; HR: 
Hazard ratio; OR: Odds ratio; SHARE: Survey of Health, Ageing and Retirement in Europe. 
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Figure 1. Flow chart of systematic literature review 
 
 
  
2611 studies identified through database searching 
   Embase (n=1790) 
   MEDLINE (n=561) 
   CINAHL Plus (n=181) 
   PsycINFO (n=79) 
6 additional studies identified through 
other sources 
1966 studies screened for titles and abstracts 
75 articles for full-text review 
Total of 2617 studies identified 
651 duplicated studies excluded 
1891 studies excluded by title and 
abstract screening 
 
19 studies for methodological quality assessment 
56 studies excluded by full-text review 
No HR/OR for mortality provided 
(n=25) 
Per groups based on FI (n=17) 
Per each additional deficit (n=4) 
Non-standard FI used (n=3) 
Same cohort used (n=3) 
Selected population (n=1)  
FI scale unknown (n=3) 
 
19 studies for meta-analysis 
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Figure 2. Forest plots of mortality risk according to frailty measured by the Frailty Index.  
A: Risk of dying (Hazard Ratio) per 0.01 increase in the Frailty Index score 
 
CI: Confidence interval, IV: inverse variance, NSHS: Nova Scotia Health Survey. 
 
B: Risk of dying (Hazard Ratio) per 0.1 increase in the Frailty Index score. 
 
BWHHS: British Women’s Heart and Health Study, CI: Confidence interval, IV: inverse 
variance, MRC: MRC assessment study.  
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Table 1. Summary of included studies on Frailty Index and mortality. 
Author/Study Year Location 
Sample 
size 
Female 
(%) 
Age 
(range) 
Number of 
deficits 
Follow-up 
period 
Risk estimate 
HR/OR (95%CI) 
Adjustment 
HR per 0.01 of FI          
Searle 
Yale-PEP  
2008 USA 754 64.6% 
- 
(72-98) 
40 9 years aHR=1.03 (1.02-1.04) age, gender 
Kulminski 
Cardiovascular Health 
Study 
2008 USA 1,073 - 
- 
(>65) 
48 4 years 
HR=1.049 (1.040-
1.057) 
unadjusted 
Rockwood 
National Population 
Health Survey 
2011 Canada 14,127 54.2% 
44 
(>15) 
42 14 years aHR=1.04 (1.03-1.04) age, gender, education 
Yu 
Beijing Longitudinal 
Study of Aging (Urban 
sample) 
2012 China 2,136 51.1% 
70.1 
 (55-97) 
35 8 years 
aHR=1.042 (1.036-
1.049) 
age, gender, education 
Yu  
Beijing Longitudinal 
Study of Aging (Rural 
sample) 
2012 China 1,121 51.0% 
70.2-70.3 
(55-97) 
35 8 years 
aHR=1.041 (0.034-
1.049) 
age, gender, education 
Bennett 
Chinese Longitudinal 
Healthy Longevity 
Survey 
2013 China 6,300 53.0% 
88.9 
(80-99) 
38 4 years aHR=1.03 (1.03-1.04) age, gender 
Theou 
SHARE 
2013 Europe* 36,306 54.6% 
65.2 
(>50) 
70 2 years aHR=1.05 (1.05-1.06) age, gender 
Pena 
Nova Scotia Health 
Survey 
2014 Canada 3,227 50.1% 
48.1 
(>18) 
23 10 years aHR=1.04 (1.03-1.05) age, gender 
Blodgett 
EMAS 
2016 Europe† 2,933 0% 
60.2 
(40-79) 
39 4.4 years aHR=1.07 (1.06-1.09) age 
Hao 
Project of Longevity 
and Aging in 
Dujiangyan 
2016 China 767 68.0% 
93.7 
(90-108) 
35 4 years aHR=1.03 (1.02-1.04) age, gender, education 
Hoogendijk 
Longitudinal Aging 
Study Amsterdam 
2016 Netherlands 2,218 - 
- 
(57-88) 
32 19 years aHR=1.03 (1.03-1.04) age, gender 
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Author/Study Year Location 
Sample 
size 
Female 
(%) 
Age 
(range) 
Number of 
deficits 
Follow-up 
period 
Risk estimate 
HR/OR (95%CI) 
Adjustment 
Miller 
NHANES 
2016 USA 8,911 - 
- 
(20-) 
46 8 years aHR=1.03 (1.02-1.04) age, gender 
Mitnitski 
CSHA 
2016 Canada 1,013 61.6% 
80.8 
(>65) 
61 6 years 
aHR=1.041 (1.030-
1.052) 
age, gender 
HR per 0.1 of FI          
Kamaruzzaman 
BWHHS 
2010 UK 4,286 100% 
- 
(60-79) 
44 8.2 year aHR=1.3 (1.2-1.4) 
age, socioeconomic status, smoking, alcohol, 
marital status, living alone, housing tenure 
Kamaruzzaman 
MRC assessment study 
2010 UK 11,195 59.9% 
- 
(>75) 
44 7.9 year aHR=1.3 (1.2-1.3) 
age, gender, smoking, alcohol, marital status, 
living alone, social contact, housing tenure 
Theou 
CSHA 
2012 Canada 2,305 62.1% 
84.6 
(70-105) 
70 5 years aHR=1.25 (1.20-1.30) age, gender 
Yu 
Beijing Longitudinal 
Study of Aging (Urban 
sample) 
2012 China 2,136 51.1% 
70.1 
 (55-97) 
35 8 years aHR=1.28 (1.23-1.32) age, gender, education 
Yu 
Beijing Longitudinal 
Study of Aging (Rural 
sample) 
2012 China 1,121 51.0% 
70.2-70.3 
(55-97) 
35 8 years aHR=1.27 (1.21-1.32) age, gender, education 
Rivindrarajah 
EMAS 
2013 Europe† 2,929 0% 
59.9 
(40-79) 
39 4.3 years aHR=1.49 (1.33-1.67) age, center, smoking, partner status 
OR per 0.01 of FI          
Li 
GLOW 
2014 Canada 3,985 100% 
69.4 
(>55) 
34 3 years aOR=1.05 (1.03-1.06) age, BMI, smoking, alcohol, education 
Theou 
TILDA 
2015 UK 4,961 54.2% 
61.9 
(>50) 
66 2 years 
aOR=1.072 (1.040-
1.106) 
age, gender 
OR per 0.1 of FI          
Armstrong 
HAAS 
2015 USA 3,845 0% 
77.9 
(72-91) 
48 6 years aOR=1.73 (1.57-1.92) age, education 
Li 
GLOW 
2016 Canada 3,985 100% 
69.4 
(>55) 
34 3 years aOR=1.33 (0.87-2.03) age 
* 15 European countries: Austria, Belgium, Czech Republic, Denmark, France, Germany, Greece, Ireland, Israel, Italy, Netherlands, Poland, 
Spain, Sweden, Switzerland 
† 8 European countries: Belgium, Estonia, Hungary, Italy, Poland, Spain, Sweden, UK 
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95%CI= 95% confidence interval 
(a)HR: (adjusted) Hazard ratio 
(a)OR: (adjusted) Odd ratio 
BMI: Body mass index 
BWHHS: British Women’s Heart and Health Study  
CSHA: Canadian Study of Health and Aging 
EMAS:  European Male Ageing Study 
GLOW: Global Longitudinal Study of Osteoporosis in Women 
FI: frailty index 
NHANES: National Health and Nutrition Examination Survey 
SES: Socioeconomic status 
SHARE: Survey of Health, Ageing and Retirement in Europe 
TILDA: The Irish LongituDinal study on Ageing 
Yale-PEP: Yale Precipitating Events Project 
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Appendix 1. 
Methodological quality assessment 
Each of the eligible studies was further examined for methodological quality using the 
Newcastle-Ottawa scale for cohort studies.[21] This scale consists of nine items regarding 
selection (4 items), compatibility (2 items) and outcome (3 items) domains of cohort studies. 
The third item in the selection domain (ascertainment of exposure) was modified to confirm 
whether a study constructed the FI in accordance with the standardised method published by 
Searle et al.[14] The fourth one (demonstration that outcome of interest was not present at 
start of study) was not used in this study since the outcome of interest was mortality. A study 
was considered to have adequate quality of methodology and was included in the meta-
analysis if four or more items out of eight were met by the modified scale. 
 
 
Statistical analysis 
The HR or OR along with 95% CI per 0.10 or 0.01 increase in the FI were extracted from the 
included studies and were used for the meta-analysis. The meta-analysis was conducted using 
the generic inverse variance method. Heterogeneity across the studies was assessed using 
Cochran’s Q statistic and I2 statistic. When p value of Cochran’s Q statistic was less than 
0.05, the studies were combined using a random-effects model. Otherwise a fixed-effects 
model was used. The studies with I2 value of 25%, 50% and 75% were considered to have 
low, moderate and high degree of heterogeneity.[22] When significant heterogeneity was 
observed in the studies, its potential cause was explored by subgroup analysis and meta-
regression analysis. Publication bias was assessed using Begg-Mazumdar’s and Egger’s tests 
and visually inspecting a funnel plot. 
 
All statistical analyses were conducted using Review Manager 5 (version 5.2, The Cochrane 
Collaboration, Copenhagen, Denmark) and Comprehensive Meta-Analysis (version 3.3, 
Biostat, New Jersey, USA). The level of statistical significance was set at P<0.05. 
 
 
Meta-regression and subgroup analysis 
A high degree of heterogeneity was observed among 13 cohorts with HR of mortality per 
0.01 increase in the FI and was explored using meta-regression analysis. Several study 
characteristics examined included publication year, location (Europe vs no Europe, US vs no 
US, Canada vs no Canada), sample size, female proportion, mean age, the number of deficits 
used for the FI, follow-up period, additional adjustment other than only age and gender and 
methodological quality score based on the modified eight-item Newcastle-Ottawa scale. 
Three[18, 34, 39] and Four[14, 18, 34, 39] studies did not report female proportion and mean 
age, respectively, and were not included in the analyses for each characteristic. The results 
suggested that two factors were significantly associated with higher mortality risks by the FI: 
(1) shorter follow-up periods (coefficient=-0.001, p=0.04, R2 analog=0.24); and (2) lower 
female proportion of the studies (coefficient=-0.0005, p=0.002, R2 analog=0.31). Appendix 5 
A and B show the bubble plots for the follow-up periods and female proportion. 
Heterogeneity of four cohorts with the follow-up periods of nine years or more decreased 
(I2=14%), while the high heterogeneity remained among nine studies with follow-up periods 
of eight years or less (I2=86%). Mortality risk according to frailty of  the studies with follow-
up of nine years or more was significantly lower than that of the studies with follow-up of 
eight years or less (p for difference=0.007). Excluding one male-only cohort[37] made little 
change to the high heterogeneity among the remaining 12 cohorts with mixed-gender 
populations (pooled HR=1.04, 95%CI=1.03-1.04, p<0.001, I2=83%). 
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Publication Bias Assessment 
The 13 cohorts providing HR per 0.01 increase in the FI and six cohorts providing HR per 0.1 
increase in the FI were assessed for publication bias. No significant publication bias was 
observed by Begg-Mazumdar’s (p=0.57 and 0.34, respectively) or Egger’s test (p=0.37 and 
0.08, respectively). The funnel plots did not show obvious asymmetry. Begg-Mazumdar’s and 
Egger’s tests could not be done due to the small number of the included studies for the 
cohorts with OR per 0.01 increase of the FI (n=2) and the cohorts with OR per 0.1 increase of 
the FI (n=2). 
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Appendix 2. A summary of the excluded studies examining mortality risk by the Frailty Index. 
Author/Study(Location)/Year 
Sample 
size 
Female 
(%) 
Age 
(range) 
Follow-up 
period 
Number of 
deficits 
How FI was used as a predictor 
variable 
Effect measure for mortality risk (95%CI, p value) 
Shi[1] 
BLSA (China) 2011 
3,257 51.1% (>55) 8 years 35 per deficit 
HR=1.13 (1.09-1.47) adjusted for age and gender. 
Drubbel[2] 
(Netherlands) 2013 
1,679 58.8% 
73 
(65-81) 
2 years 36 per deficit 
HR=1.166 (1.129-1.210, p=0.05) for combined outcomes 
(mortality, emergency department or out-of-hours GP surgery 
visits and nursing home admission), adjusted for age, gender 
and consultation gap. 
Song[3] 
CSHA (Canada) 2014 
7,239 59.9% 
- 
(>65) 
10years 42 per deficit 
Age-adjusted OR=1.22 (1.18-1.26) for men and 1.14 (1.11-
1.16) for women. 
Yang[4] 
Chinese Longitudinal Healthy 
Longevity Survey (China) 
2016 
13,731 57.3% 
- 
(>65) 
3 years 39 per deficit 
HR by Weibull hazard models=1.04 to 1.10 in all age groups of 
65-79, 80-89, 90-99, and 100+ (all p<0.001) both in men and 
women, adjusted for age, ethnicity, residence, marital status, 
education, occupation, economic independence, economic 
status, co-residence with family, smoking, and exercise. 
Bartley[5] 
Mayo Clinic Study of Aging 
(USA) 2016 
2,356 49.8% 
78.8 
(70-89) 
6.5 years 36 
(i) per deficit 
(ii) 4 groups 
(cut-points: 0.10, 0.20, 0.30) 
(i) HR=1.12 (1.10-1.15, p<0.001) adjusted for age, gender and 
education. 
(ii) HR=1.47 (1.03-2.10, p=0.03), 2.65 (1.86-3.78, p<0.001) 
and 3.91 (2.69-5.68, p<0.001) for groups 0.11-0.20, 0.21-0.30 
and >0.30, respectively (reference group= 0-0.10). 
Hyde[6] 
Australia (Aboriginal 
Australians) 2016 
363 54.5% 
60.7 
(45-96) 
6.7 years 20 
(i) per deficit 
(ii) 2 groups 
(cut-point 0.2) 
(i) HR=1.14 (1.1-1.2) adjusted for age and gender. 
(ii) HR=1.9 (1.2-3.0) adjusted for age and gender. 
Lucicesare[7] 
Conselice Study of Brain 
Aging 
(Italy) 2010 
1,016 55.4% 
74.7 
(>65) 
4 years 43 
apparently 2 groups 
(cut-point=0.25) 
HR=5.26 (1.05-26.42, p=0.04) adjusted for age ,gender and 
Conselice Study of Brain Aging score. 
Tang[8] 
BLSA (China) 2013 
3,257 51.1% 
70.1 
(>55) 
15 years 35 
2 groups 
(cut point: 0.22) 
HR=2.06 (1.82-2.32, p<0.01) adjusted for age, gender and 
education. 
Widagdo[9] 
Australian Longitudinal Study 
of Ageing (Australia) 2015 
2,087 49.4% 
78.2 
(>65) 
3 years 39 
2 groups (frailty or not) 
(cut-point 0.25) 
OR=3.2 (2.4-4.1). 
Kulminski[10] 
Cardiovascular Health Study 
(USA) 2008 
4,721 - 
- 
(>65) 
4 years 48 
3 groups (robust, prefrail, frail) 
(cut-points: 0, 0.4) 
Unadjusted HR=1.94 (1.45-2.61) for prefrail and 4.45 (3.26-
6.08) for frail. (reference group: robust). 
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Author/Study(Location)/Year 
Sample 
size 
Female 
(%) 
Age 
(range) 
Follow-up 
period 
Number of 
deficits 
How FI was used as a predictor 
variable 
Effect measure for mortality risk (95%CI, p value) 
Malmstrom[11] 
(USA) 2014 
998 - (49-65) 9 years 25 
3 groups (robust, prefrail, frail) 
(cut-points: 0.20, 0.25) 
OR=1.77 (0.92-3.41, p=0.08) for prefrail and 2.28 (1.46-3.55, 
p<0.001) for frail adjusted for age and gender (reference 
group=robust) 
Song[12] 
National Population Health 
Survey of Canada (Canada) 
2010 
2,740 60.8% 
74.0 
(65-
102) 
10 years 36 
3 groups 
(cut-points: 0.08, 0.25) 
HR=1.57 (1.41-1.74) adjusted for age and gender. 
Wang[13] 
BLSA (China) 2013 
3,257 51.1% 
- 
(>55) 
15 years 28 
3 groups 
(cut-points: 0.08, 0.15) 
Higher frailty levels associated with higher mortality risk in 
both smokers and non-smokers. 
Li[14] 
Global longitudinal study of 
osteoporosis in women 
(Canada) 2015 
3,985 100% 
69.4 
(>55) 
3.01 years 34 
(i) 3 groups 
(cut-points: 0.20, 0.35) 
(ii) 3 groups  
(mean: 0.18, 0.29, 0.35) 
(iii) 5 groups  
(cut-points: 0.14, 0.28, 0.42, 0.56)) 
(i) HR=1.95 (1.06-3.61) for intermediate frailty and 4.26 (2.34-
7.76) for high frailty. 
(ii) HR=2.46 (1.39-4.36) for intermediate frailty and 478 (2.65-
8.63) for high frailty. 
(iii) HR=1.81 (1.46-2.24) with each increment in FI grouping. 
All models adjusted for age, smoking, alcohol, BMI and 
education. 
Clegg[15] 
Health Improvement Network 
databases (UK) 2016 
207,720 
516,007 
55% 
56% 
- 
(65-95) 
1, 3, 5 
years 
36 
4 groups 
(cut-points: 0.12, 0.24, 0.36) 
1, 3 and 5 year-mortality HR=1.66-1.92, 2.54-3.10 and 3.83-
4.52 adjusted for age and gender for groups >0.12-0.24, >0.24-
0.36 and >0.36, respectively (reference group=0-0.12). 
Gu[16] 
Chinese Longitudinal Healthy 
Longevity Survey (China) 
2009 
13,861 57.2% 
- 
(65-
109) 
3 years 39 
4 groups 
(quartile) 
HR by Weibull hazard models=1.18-2.12 for 2nd quartile, 1.55-
2.38 for 3rd quartile and 2.41-4.56 for 4th quartile, stratified by 
age and gender adjusted for age ethnicity, residence, 
socioeconomic status, family/social connection and support and 
health practices (reference group=1st quartile). 
Fang[17] 
BLSA (China) 2012 
3,257 51.1% 
70.1 
(>55) 
8 years 33 
5 groups 
(cut points: 0.03, 0.10, 0.20, 0.50) 
OR=1.50 (1.41-1.60) adjusted for age, gender and education. 
HR=1.29 (1.25-1.33) adjusted for age, gender, education, falls 
and fractures. 
Garcia-Gonzalez[18] 
Mexican Health and Aging 
Study (Mexico) 2009 
4,082 52.5% 
73 
(>65) 
2 years 34 
5 groups 
(cut-points: 0.07, 0.14, 0.21, 0.35) 
HR=0.93 (0.58-1.50), 1.56 (1.00-2.44), 2.20 (1.42-3.41), 6.45 
(4.10-10.14) for 2nd, 3rd, 4th and 5th groups adjusted for age 
and gender (reference group=1st group). 
Saum[19] 
ESTHER (Germany) 2014 
9,886 54.9% 
62.0 
(50-75) 
8.7 years 34 
5 groups 
(tertile) 
HR=1.08 (0.84-1.39), 1.32 (1.05-1.66), 1.77 (1.41-2.22) and 
2.60 (2.11-3.20) for 2nd, 3rd, 4th and 5th quintile adjusted for 
age, gender and smoking (reference group=1st quintile). 
Armstrong[20] 
Honolulu-Asia Aging Study 
(USA) 2015 
3,801 0% 
77.9 
(71-93) 
21 years 36 
6 groups 
(cut-points: 0.05, 0.15, 0.25, 0.35, 
0.5) 
HR=1.44 (1.39-1.49) with each increment in FI grouping. 
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Author/Study(Location)/Year 
Sample 
size 
Female 
(%) 
Age 
(range) 
Follow-up 
period 
Number of 
deficits 
How FI was used as a predictor 
variable 
Effect measure for mortality risk (95%CI, p value) 
Jones[21] 
CSHA (Canada) 2005 
3,736 38.3% 
- 
(>65) 
5 years 14 
7 groups  
(cut-points: 0.23, 0.31, 0.40, 0.48, 
0.60, 0.74) 
HR=1.23 (1.18-1.29) with each increment in FI grouping 
adjusted for age, gender and education. 
Mitnitski[22] 
CSHA (Canada) 2011 
2,305 62.1% 
- 
(>70) 
5 years 47 
7 groups 
(not specified) 
OR=1.56 adjusted for age, gender and baseline cognitive error 
state. 
Howlett[23] 
CSHA (Canada) 2014 
1,013 - 
- 
(>65) 
6 years 
61 
(including 
23 blood 
test results) 
per 0.01 increase of FI 
HR=1.04 (1.03-1.05) per 0.01 increase adjusted for age and 
gender. 
Davis[24] 
CSHA (Canada) 2011 
1,295 - 
- 
(>65) 
5 years not shown per 0.01 increase of FI 
HR=1.04 (1.02, 1.06, p<0.05) adjusted for age and gender. 
Gu[25] 
CLHLS (China) 2015 (Female) 
3,557 100% 
- 
(>100) 
3.7 years 39 per 0.01 increase of FI 
HR=1.016 (1.014-1.018) adjusted for “demographics, 
socioeconomic status, and health practice” 
Gu[25] 
CLHLS (China) 201 5(Male) 
877 0% 
- 
(>100) 
3.7 years 39 per 0.01 increase of FI 
HR=1.014 (1.010-1.018) adjusted for “demographics, 
socioeconomic status, and health practice” 
Song[26] 
CSHA (Canada) 2007 
8,547 59.5% 
- 
(>65) 
6 years 40 “each increment in the FI” 
HR=1.38 (1.14-1.72) and 1.18 (1.11-1.26) in rural and urban 
participants, respectively. 
Kulminski[27] 
Framingham Heart Study 
(USA) 2008 
5,882 59.7% 
- 
(44-88) 
24 years 39 not shown 
HR=1.62 (1.53-1.71) adjusted for age, gender, smoking and 
BMI. 
Rockwood[28] 
CSHA (Canada) 2005 
2,305 - 
- 
(>65) 
5 years 70 not shown 
HR=1.26 (1.24-1.29) adjusted for age, gender and education. 
BLSA: Beijing Longitudinal Study of Ageing 
CI: Confidence interval 
CLHLS: Chinese Longitudinal Health and Longevity Study 
CSHA: Canadian Study of Health and Aging 
FI: Frailty index 
HR: Hazard ratio 
OR: Odds ratio 
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Appendix 4. Forest plots of mortality risk according to frailty measured by the 
Frailty Index. 
 
A: Odds of dying (Odds Ratio) per 0.01 increase in the Frailty Index score 
 
CI: Confidence interval, IV: inverse variance 
 
B: Odds of dying (Odds Ratio) per 0.1 increase in the Frailty Index score. 
 
CI: Confidence interval, IV: inverse variance 
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Appendix 5. Bubble plots for the follow-up periods (A) and female proportion (B) 
A 
 
 
B 
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